US 12,138,274 B2
Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases
Hanjun Wang, Omaha, NE (US); Dong Wang, Omaha, NE (US); Thomas Nicholas, Omaha, NE (US); Michael Lankhorst, Elkhorn, NE (US); Steven Lisco, Omaha, NE (US); Irving Zucker, Omaha, NE (US); Lie Gao, Omaha, NE (US); and Juan Hong, Omaha, NE (US)
Assigned to BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, Lincoln, NE (US)
Appl. No. 17/290,912
Filed by BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, Lincoln, NE (US)
PCT Filed Nov. 8, 2019, PCT No. PCT/US2019/060439
§ 371(c)(1), (2) Date May 3, 2021,
PCT Pub. No. WO2020/097442, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/757,406, filed on Nov. 8, 2018.
Claims priority of provisional application 62/757,410, filed on Nov. 8, 2018.
Prior Publication US 2021/0386764 A1, Dec. 16, 2021
Int. Cl. A61K 31/65 (2006.01); A61K 9/00 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61P 9/14 (2006.01)
CPC A61K 31/65 (2013.01) [A61K 9/0019 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61P 9/14 (2018.01)] 23 Claims
 
1. A method for inhibiting or treating peripheral artery disease and/or associated symptoms in a subject, said method comprising administering an inhibitor of macrophage activation and/or activity to said subject,
wherein said inhibitor is administered via intra- or peri-ganglion injection, intra-dorsal root ganglion (DRG) injection, or epidural injection.